×
About 1,853 results

ALLMedicine™ Kaposi Sarcoma Center

Research & Reviews  683 results

Natural History of KSHV-Associated Multicentric Castleman s Disease
https://clinicaltrials.gov/ct2/show/NCT04968288

Oct 22nd, 2021 - Background: Multicentric Castleman s disease (MCD) is a rare but lethal Kaposi s sarcoma-associated herpesvirus (KSHV) associated lymphoproliferative disorder with a historical median survival of 2 years. It occurs more often in HIV-infected indiv...

Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
https://clinicaltrials.gov/ct2/show/NCT02595866

Oct 21st, 2021 - PRIMARY OBJECTIVES: I. To assess the safety and tolerability of MK-3475 (pembrolizumab) in HIV-infected patients on effective antiretroviral therapy and with relapsed/refractory or disseminated acquired immune deficiency syndrome (AIDS)-defining o...

Long-term outcomes for children and adolescents with Kaposi sarcoma.
https://doi.org/10.1111/hiv.13191
HIV Medicine; Silverstein A, Kamiyango W et. al.

Oct 12th, 2021 - Kaposi sarcoma (KS) is one of the most common childhood cancers in eastern and central Africa. It has become a treatable disease with increasing availability of antiretroviral therapy (ART) and chemotherapy. We aimed to fill the data gap in establ...

Merkel cell carcinoma in a young man with AIDS-related Kaposi sarcoma.
https://doi.org/10.1111/cup.14146
Journal of Cutaneous Pathology; Schiele K, Kojder PL et. al.

Oct 9th, 2021 - Merkel cell carcinoma (MCC) is a rare, aggressive primary neuroendocrine carcinoma of the skin that can present in immunocompromised patients. Kaposi sarcoma (KS) is an indolent angioproliferative tumor associated with human herpesvirus 8 (HHV8). ...

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
https://clinicaltrials.gov/ct2/show/NCT04893018

Oct 6th, 2021 - OUTLINE: This is a dose-escalation study. Patients receive efineptakin alfa intramuscularly (IM) on day 1. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of study tr...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  7 results

Natural History of KSHV-Associated Multicentric Castleman s Disease
https://clinicaltrials.gov/ct2/show/NCT04968288

Oct 22nd, 2021 - Background: Multicentric Castleman s disease (MCD) is a rare but lethal Kaposi s sarcoma-associated herpesvirus (KSHV) associated lymphoproliferative disorder with a historical median survival of 2 years. It occurs more often in HIV-infected indiv...

Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
https://clinicaltrials.gov/ct2/show/NCT02595866

Oct 21st, 2021 - PRIMARY OBJECTIVES: I. To assess the safety and tolerability of MK-3475 (pembrolizumab) in HIV-infected patients on effective antiretroviral therapy and with relapsed/refractory or disseminated acquired immune deficiency syndrome (AIDS)-defining o...

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
https://clinicaltrials.gov/ct2/show/NCT04893018

Oct 6th, 2021 - OUTLINE: This is a dose-escalation study. Patients receive efineptakin alfa intramuscularly (IM) on day 1. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of study tr...

Pomalidomide Treatment in Patients With Kaposi Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04577755

Sep 5th, 2021 - PRIMARY OBJECTIVE: I. To assess the proportion of participants with Kaposi sarcoma (KS) (with or without human immunodeficiency virus [HIV], regardless of previous treatment status) treated with pomalidomide who respond to treatment with a durable...

Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04065152

Aug 22nd, 2019 - Kaposi Sarcoma (KS) is a lymphangioproliferation associated with human herpes virus 8 (HHV8) promoted by immunosuppression. HIV-related KS and iatrogenic posttransplantation KS are treated by immune restoration, in association with local or system...

see more →

News  45 results

2020 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2020-approvals-expand-access-to-care-for-patients-across-tumor-types

Feb 4th, 2021 - In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020. In total, 21 novel agents were approved across hematology/ oncology, including 3 diagnostic imaging ...

Merkel Cell Carcinoma Study Matches TMB With Disease Drivers
https://www.onclive.com/view/merkel-cell-carcinoma-study-matches-tmb-with-disease-drivers

Dec 5th, 2020 - The molecular profile of Merkel cell carcinoma (MCC) differs depending upon whether the malignancy is driven by ultraviolet (UV) light or by a virus and can be correlated with responses to immunotherapy, according to recent study findings. Invest...

Inaugural Guidelines for Patients With HIV Aim to Expand Therapy Options
https://www.onclive.com/view/inaugural-guidelines-for-patients-with-hiv-aim-to-expand-therapy-options

Dec 5th, 2020 - Gita Suneja, MD The HIV status of a patient who is living with the infection and has been diagnosed with cancer may be a component of a diagnostic workup but should not be the sole determining factor in making decisions about treatment, according...

FDA Approves Pomalidomide for Kaposi Sarcoma
https://www.onclive.com/view/fda-approves-pomalidomide-for-kaposi-sarcoma

Dec 4th, 2020 - The FDA has granted an accelerated approval to pomalidomide (Pomalyst) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or in patients with Kaposi sarcoma who are HIV...

FDA Grants Pomalidomide Breakthrough Designation in Kaposi Sarcoma
https://www.onclive.com/view/fda-grants-pomalidomide-breakthrough-designation-in-kaposi-sarcoma

Dec 4th, 2020 - Jay Backstrom, MD The FDA has granted a breakthrough therapy designation to pomalidomide (Pomalyst) for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative K...

see more →

Patient Education  4 results see all →